Objectives: A retrospective study was conducted to elucidate contributing factors on the outcome of patients with vasospastic angina. Subjects and methods: Two hundred ninety-two patients with angina in whom coronary vasospasm was documented were followed up (mean 4.3 ± 3.6 years) to determine the relationship between the occurrence of cardiovascular events with available clinical factors including therapeutic drugs. Cardiovascular events were defined as fatal and non-fatal cardiovascular disorder events. Results: Several clinical variables including age, elevated creatinine level, low highdensity lipoprotein (HDL) cholesterol level, presence of severe coronary artery stenosis, low left ventricular ejection fraction, low cardiac index (CI), large left ventricular mass, and use of beta-blockers proved to be significant risk factors for cardiovascular events. Further analysis by a stepwise regression analysis revealed that, older age (hazard ratio (HR) = 1.42), low HDL cholesterol level (HR = 0.877), presence of severe coronary artery stenosis (HR = 49.32), and decreased CI (HR = 14.18) proved to be independent prognostic factors. Ca antagonists were prescribed to 261 patients (89.4%). Among four Ca antagonists, there were significant differences in the frequency of cardiovascular events (2.6% with benidipine, * Corresponding author. 4.2% with nifedipine, 6.0% with diltiazem, 23.1% with amlodipine; amlodipine vs. benidipine, P < 0.05) although the background characteristics of the four different patient groups were non-equivalent. Conclusion: These results indicate that the morbidity of patients with vasospastic angina increased with older age, lower CI or HDL cholesterol, and presence of severe coronary artery stenosis, and that treatment with benidipine appeared to reduce cardiovascular events in patients with vasospastic angina.
Introduction
Coronary artery spasm is involved in various coronary arterial diseases, such as vasospastic angina, myocardial infarction and sudden death. Coronary vasospasm is caused by abnormal contraction of coronary vascular smooth muscles, and one cause of its occurrence seems to be vascular endothelial dysfunction [1] . It is believed that endothelial dysfunction including decreased nitric oxide production (NO) [2, 3] leads to abnormalities in the maintenance of vascular tonus, and as a result, sympathetic nerve activation at rest in the early morning, cold stimuli, excessive alcohol consumption, and other provocative factors result in abnormal contraction of coronary vascular smooth muscles.
Some researchers have reported the incidence of patients with vasospastic angina in Japan. Pristipino et al. compared the response to acetylcholine in infarct-related lesions and non-infarct-related lesions between Japanese and Caucasian patients with acute myocardial infarction, and demonstrated that coronary spasm is three times more frequent in the Japanese than in the Caucasians [4] . In a multi-center study performing a spasm provocation test by Yasue et al., as many as 40-60% of patients with angina had coronary vasospasm. Although the frequency is different among areas or institutions, vasospastic angina may account for a very high proportion of angina types [5] [6] [7] . High frequency of coronary vasospasm in the Japanese is attributed to racial differences in the involved genes [8] [9] [10] [11] .
In general Ca antagonists are useful for the long-term outcome of vasospastic angina [12] . However, sudden death or myocardial infarction may occur in some patients with active vasospasm, and they should be carefully followed up. Coronary vasospasm is most commonly treated with continuous oral administration of coronary vasodilators represented by Ca antagonists. On the other hand, notwithstanding the large number of patients with vasospastic angina, reports are limited on the risk factors for cardiovascular diseases and the choice of therapeutic drugs improving long-term survival [12] [13] [14] , and further studies are required.
We therefore retrospectively studied the effects of patients' characteristics and therapeutic drugs on the incidence of cardiovascular events in those hospitalized in Fukuoka University Chikushi Hospital and diagnosed with vasospastic angina.
Patients and methods

Subjects and procedures
Out of 387 patients with vasospastic angina treated at the cardiovascular division of our hospital from May 1987 to June 2006, 292 could be followed up and were enrolled in the study. Coronary arteriography was performed in all patients with chest pain attacks at rest. The administration of coronary vasodilators including Ca antagonists and NO donors was stopped before coronary arteriography. Patients were diagnosed with vasospastic angina when spasm was provoked by administering acetylcholine into the coronary artery. Before the spasm provocation test with acetylcholine, a control arteriography was performed. Acetylcholine was then injected from the same angle into the right coronary artery at 10 g, 30 g, or 50 g and into the left coronary artery at 10 g, 30 g, 50 g, or 100 g each over 1 min. Coronary spasm was defined as total or subtotal obstruction (i.e. >99%) associated with an attack of chest pain, ischemic ST-segment changes on the electrocardiogram (ECG), or both [15] . The test was discontinued when coronary spasm was induced.
Considering the results of a questionnaire and measurements of blood biochemical parameters and cardiac function at the time of diagnosis of vasospastic angina, the following variables were investigated from the medical record as patients' characteristics: gender, age, body mass index (BMI), family history of ischemic heart diseases, smoking history, drinking history, complications (history of hypertension, dyslipidemia, diabetes mellitus, impaired glucose tolerance, myocardial infarction, Complications were diagnosed according to the following guidelines: ''Japanese Society of Hypertension Guidelines'' for hypertension, ''Japan Atherosclerosis Society Guidelines'' for dyslipidemia, ''Japan Diabetes Society Guidelines'' for diabetes and abnormal glucose tolerance, and ''Japanese Circulation Society Guidelines'' for ischemic heart diseases. Stenosis of the coronary artery was evaluated by coronary arteriography after nitroglycerine injection according to the American Heart Association (AHA) classification. Stenosis of >75% in one or more branches of any of the right coronary artery (RCA), left main trunk artery (LMT), left circumflex artery (LCX), or left anterior descending artery (LAD) was regarded as significant coronary artery stenosis. Oral medications such as Ca antagonists, statins, nitrates, aspirin, nicorandil, and beta-blockers were also investigated.
Subjects were followed up by mail or phone from the time of diagnosis with vasospastic angina to October 1, 2006 to investigate survival and occurrence of cardiovascular events. Cardiovascular events were defined as fatal cardiovascular disorder and non-fatal events. Fatal cardiovascular disorder included death due to sudden death, acute myocardial infarction, cerebrovascular disorder, heart failure, and aortic aneurysm. Non-fatal events included occurrence of acute myocardial infarction, cerebrovascular disorder, heart failure, aortic aneurysm, renal failure, and obstructive atherosclerosis, as well as undergoing cardiac surgery such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).
Statistical analysis
All data were expressed with mean ± standard deviation (S.D.) and statistically analyzed using computer software, SPSS for Windows, Ver.11.0.1 (SPSS Japan Inc., Tokyo, Japan). The level of significance was set at 0.05 (two-tailed). Differences were considered statistically significant when the Pvalue was less than 0.05. Patients' characteristics that may affect the outcome of vasospastic angina and the efficacy of therapeutic drugs were analyzed by univariate logistic regression and Cox regression to calculate odds and hazard ratios, respectively. The cardiovascular event-free curves were plotted by the Kaplan-Meier method and compared using the log-rank test.
Results
Clinical features of patients
A total of 292 of 382 patients (75.4%) could be followed up and the mean follow-up was 4.1 ± 3.6 years. Table 1 shows the characteristics of the whole population and of patients stratified by the presence or absence of cardiovascular events. The mean age was 64.1 years, the male to female ratio was 59 to 41, and 34% and 55% of patients had smoking and drinking habits, respectively. The most common complications were hypertension and dyslipidemia in 45% and diabetes in 15% (17% including abnormal glucose tolerance).
Cardiovascular events occurred in 16 patients (5.5%), fatal cardiovascular disease in 1 and nonfatal cardiovascular events in 15. Patients who suffered from cardiovascular events were older and had lower HDL cholesterol level and higher creatinine level than event-free patients. They also showed lower cardiac function (LVEF, CI) and higher incidence of coronary artery stenosis. The use of beta-blockers was associated with a higher frequency of cardiovascular events. Other drugs (Ca antagonists, statins, nitrates, aspirin, nicorandil) did not affect the outcome.
Prognostic factors in patients with vasospastic angina
The relationship between patients' characteristic and cardiovascular events shown in Table 1 was analyzed by univariate logistic regression. The eight variables shown in Table 2 had a significant relationship with cardiovascular events. In addition to these characteristics, the factors reported in the literature to predict the outcome of vasospastic angina (gender, hypertension, smoking habit, diabetes and abnormal glucose tolerance, Ca antagonists) and other therapeutic drugs (statins, nitrates, aspirin, nicorandil) were included in the Cox regression analysis. The results are shown in Table 2 . Four variables, coronary artery stenosis, decreased CI, high age, and low HDL cholesterol level, were independent prognostic factors for cardiovascular events in vasospastic angina, and the hazard ratios were higher in this order. The Kaplan-Meier curves 
Values are mean ± S.D., or frequency counts, as appropriate. BMI, body mass index; LVEF, left ventricular ejection fraction; CI, cardiac index; LVDd, left ventricular diastolic dimension; LVmass, left ventricular mass; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BNP, plasma brain natriuretic peptide; CRP, C-reactive protein; WBC, white blood cell count. for cardiovascular event-free survival are shown in Fig. 1 for these four variables.
Effects of Ca antagonists on long-term survival in patients with vasospatic angina
Ca antagonists were prescribed to 89.4% of patients; diltiazem to 151, benidipine to 78, nifedipine to 24, and amlodipine to 13. Eleven patients received more than two Ca antagonists. The mean dose was 149.4 ± 50.3 mg for diltiazem, 4.1 ± 1.5 mg for benidipine, 30.0 ± 10.3 mg for nifedipine, and 5.0 mg for amlodipine. The mean follow-up of patients receiving Ca antagonists was 4.3 ± 4.0 years for diltiazem, 3.5 ± 2.9 years for benidipine, 3.6 ± 3.5 years for nifedip- ine, and 3.6 ± 3.5 years for amlodipine. There were no significant differences in the rates of other drug treatment including anti-hypertensive, antidyslipidemia, anti-coagulants, etc. Table 3 shows the incidence of cardiovascular events by Ca antagonists. The frequency of cardiovascular events was 2.6% in the group treated with benidipine, 4.2% with nifedipine, 6.0% with diltiazem, and 23.1% with amlodipine. Table 4 summarizes the background characteristics of four different patient groups treated with four different Ca antagonists (diltiazem, benidipine, nifedipine, and amlodipine). There were significant differences in the prevalence of hypertension, impaired glucose tolerance, and low HDL-cholesterol among the four groups, although the number of patients categorized into four different groups were not equivalent. In order to examine the difference of the four different Ca antagonists, Kaplan-Meier analysis for cardiovascular event-free survival was performed (Fig. 2) . Benidipine and diltiazem provided an equivalent benefit to suppress cardiovascular events in patients with vasospastic angina, while amlodipine showed a significantly worse outcome compared to benidipine. Namely, the occurrence of cardiovascular events was significantly higher in the amlodipine group compared to the benidipine group (P < 0.05).
Discussion
Clinical features and prognostic factors in patients with vasospastic angina
Long-term follow-up for more than 4 years in 292 patients with vasospatic angina revealed that high age, low serum HDL cholesterol level, presence of severe coronary artery stenosis, and decreased CI were significant detrimental prognostic factors.
This study demonstrated for the first time that decreased CI is an independent poor prognostic factor, in addition to severe stenosis of the coronary artery and high age which have been previously reported [14, 16] . It also showed that a low HDL cholesterol level is a risk factor for poor outcome. Previous reports [16, 17] suggested a relationship between dyslipidemia and coronary spasm. Yamagishi et al. reported that a high LDL cholesterol level (>140 mg/dl) is a poor prognostic factor in patients with vasospastic angina without severe coronary artery stenosis [16] and Miwa reported low HDL cholesterol levels in patients with vasospastic angina [17] . The relationship between coronary spasm with triglycerides and obesity was not demonstrated in this study, but it was possible that abnormal lipid metabolism including low HDL cholesterol level caused endothelial dysfunction, atherosclerosis, stenosis of the coronary artery, and consequently cardiovascular events.
Our data revealed that low CI was an independent predictive risk factor for cardiovascular events in patients with vasospastic angina. It has been generally considered that vasospasm is associated with temporal, but not chronic, decrease in cardiac output. Although short-term myocardial ischemia caused by vasospasm may cause a temporal myocardial stunning and low output status, the observed low CI in the present study was not transient and, therefore, was not directly caused by vasospasm, rather by other preexisting confounding factors such as previous myocardial ischemia and hypertensive heart failure.
Stenosis of the coronary artery has been reported to be a risk factor for vasospastic angina [16, 18] , which is in accordance with our present results. LVmass, left ventricular mass; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BNP, plasma brain natriuretic peptide; CRP, C-reactive protein; WBC, white blood cell count.
stenosis (more than 50% stenosis) in 256 patients with vasospastic angina is an independent contributing factor for cardiovascular events (hazard ratio of 2.84) compared with patients without coronary artery stenosis [16] . Kido et al. also reported that, in both sexes, the coronary sclerosis indices in the vasospasm positive group were higher than those in the negative group [18] . Thus, significant coronary artery stenosis appears to be an independent risk factor for cardiovascular events in patients with vasospastic angina. The detailed mechanism of how coronary artery lesions affect the long-term outcome of vasospastic angina has not yet been determined, but it is likely that a significant organic stenosis is linked with multiple risk stratification, such as aging, hypertension, dyslipidemia, and low HDL-cholesterol level. Our present data suggest that each of these risk factors was also an independent predictive factor for cardiovascular events in patients with vasospastic angina.
Obviously, a future prospective study is necessary to determine how severe coronary artery stenosis is linked to cardiovascular events in patients with vasospastic angina. Summarizing these findings, our data show that co-existence of coronary artery spasm and stenosis affects the long-term outcomes of vasospastic angina and their appropriate management is an important factor to reduce cardiovascular events.
Effects of therapeutic drugs on long-term survival of patients with vasospastic angina
Ca antagonists were prescribed to about 90% of patients enrolled in this study, and the use of beta-blockers was limited. Yasue et al. reported that a beta-blocker, propranolol, was ineffective and the Ca antagonists diltiazem and nifedipine were effective to significantly reduce exerciseinduced attacks of coronary spasm [19] and that Ca antagonists inhibited cardiac death and cardiovascular events in 245 patients with variant angina [12] . Recent clinical studies investigated the effects of Ca antagonists on the outcome of patients with angina and coronary artery diseases and proved their usefulness [20, 21] . As expected, Ca antagonists were the most frequently prescribed in the present study. On the other hand, use of beta-blockers was associated with increased cardiovascular events despite infrequent prescription of the drugs.
The important focus of the present study was to compare the outcome effects of different Ca antagonists because the efficacy of Ca antagonists in vasospastic angina may differ from one drug to another. A few reports are available on which Ca
antagonist is effective in patients with vasospasitic angina pectoris. Ito et al. followed up 726 patients with vasospastic angina and demonstrated that survival without cardiovascular events with benidipine was significantly higher in comparison with other Ca antagonists [14] . Sakata et al. reported that benidipine was significantly more effective to inhibit cardiovascular events than diltiazem [22] . In the present study, the outcome differed depending on the choice of therapeutic drugs. As reported by others, the frequency of cardiovascular events was least with benidipine. Although the number of amlodipine-treated patients was small, benidipine was significantly more effective in inhibiting cardiovascular events than amlodipine. The frequency of cardiovascular events with benidipine was reported by Ito et al. to be 2.0% (number of patients with cardiovascular events/number of patients treated with benidipine = 3/148), 2.9% (1/34) by Sakata et al., and 2.6% (2/78) in this study. These results were comparable with each other, and it appeared to be confirmative that benidipine improves the clinical outcome of vasospastic angina.
Various mechanisms of action may be involved in the effect of benidipine to improve the clinical outcome. Results of the present study indicated that decreased HDL cholesterol level or CI was associated with poor prognosis in vasospastic angina. In fact, it has been reported that benidipine treatment improves lipid metabolism manifested by increase in HDL cholesterol level [23, 24] and cardiac function manifested by increase in CI [25] .
It is also possible that benidipine retards the progression of atherosclerosis. The progress of atherosclerosis and promotion of oxidative stress are known to be deeply implicated in increased coronary spastic activity. Benidipine is superior to other Ca antagonists in endothelial protection [26, 27] , antioxidant properties [28] , and antiinflammatory action [29] .
Basic studies of benidipine indicated that this compound more selectively acts on the coronary vessels compared with other Ca antagonists [30, 31] and has a significant anti-spastic effect [32] . Benidipine was also reported to be useful in the clinical setting to treat vasospastic angina which cannot be sufficiently controlled with diltiazem [33] . Such multiple actions of benidipine may decrease the coronary spastic activity and inhibit cardiovascular events in the long-term.
The interpretation of the present data that benidipine appeared to be superior in the clinical outcome of the patients with vasospastic angina should be cautious because this study was a retrospective study. In fact, the patient characteristics of each group treated with the different Ca antagonists were not equivalent. As shown in Table 4 , the prevalence of hypertension, impaired glucose tolerance, and low HDL-cholesterol in the nifedipine or amlodipine groups was higher than that in benidipine group, respectively. Those are important risk factors for cardiovascular events. Among these risk factors, especially, the complication rate of hypertension in the nifedipine or amlodipine groups was significantly higher than that in other groups despite the non-equivalent patient numbers in each group. It is a well known fact that hypertension itself causes endothelial dysfunction, vascular remodeling, and the resultant systemic arteriosclerosis, which may lead to subsequent cardiovascular events. In addition, the prevalence of impaired glucose tolerance or low-HDL cholesterol, important risk factors for cardiovascular events, were also significantly different among the groups. These background differences might be linked to the outcome difference among the four Ca antagonists. A future prospective study is warranted to examine the difference among long-acting Ca antagonists in terms of the suppressive effect of cardiovascular events in patients with vasospastic angina.
Limitations
The interpretation of this retrospective, singleinstitute, study is limited by relatively small sample size and inhomogeneous patients' baseline characteristics. The findings of several important risk factors for patients with vasospastic angina and the beneficial effect of benidipine were interesting and in accordance with several previous reports. But, most of these studies were based on retrospective analysis. A prospective randomized multi-center trial is definitively necessary to identify the long-term risk factors and the differential benefit among long-acting Ca antagonists in patients with vasospastic angina.
Conclusion
This retrospective study demonstrated that several clinical conditions such as low HDL cholesterol level, presence of significant coronary stenosis, higher age, and low CI were important determinants for long-term outcome in patients with vasosopastic angina. In addition, Ca antagonists are commonly used in this disease, but the outcome differs depending on the type of Ca antagonist. Benidipine and diltiazem were equally effective on reduction of cardiovascular events in patients with vasospastic angina. 
